resiquimod

Overview

Resiquimod (also known as R848) is a synthetic imidazoquinoline compound that functions as a potent dual agonist of toll-like receptor 7 and toll-like receptor 8 (TLR7/8). By binding to these pattern recognition receptors — expressed predominantly on dendritic cells, monocytes, and other innate immune cells — resiquimod triggers downstream signaling cascades that drive the production of proinflammatory cytokines, including interleukin-12, and promote robust adaptive immune activation. This mechanism positions resiquimod as a powerful immunostimulatory agent with broad relevance to infectious disease, oncology, and vaccine adjuvant research.

In the cancer immunotherapy setting, resiquimod is of particular interest because its TLR7/8 agonism can repolarize the immunosuppressive tumor microenvironment, activate antigen-presenting dendritic cells, and potentiate T-cell-mediated cytotoxic responses against tumour cells. However, its clinical translation has been limited by systemic toxicity arising from nonspecific immune activation and poor tumor-site targeting when administered as a free drug. As a result, a significant body of recent research has focused on encapsulating or chemically modifying resiquimod within advanced delivery platforms to confine its immunostimulatory activity to the tumor compartment while minimizing off-target effects.

Focus of Latest Publications

Recent literature demonstrates a convergent focus on two complementary strategies for harnessing resiquimod in cancer immunotherapy: (1) nanomaterial-based co-delivery with cytotoxic agents to achieve synergistic chemo-immunotherapy, and (2) chemical derivatization to improve tumor selectivity.

A central theme across multiple studies is the pairing of resiquimod with paclitaxel, a first-line cytotoxic chemotherapy agent. One study developed a reactive oxygen species (ROS)-responsive nanoplatform based on mPEG-PCL polymer nanoparticles for the co-delivery of a paclitaxel prodrug and resiquimod (R848). The ROS-sensitive design enables tumor-localized drug release, exploiting the oxidative environment characteristic of the tumor microenvironment to trigger payload liberation, thereby combining direct cancer cell killing with TLR7/8-mediated immune priming. Separately, a study employing phenylboronic acid (PBA) modification of resiquimod developed a derivative intended to improve tumor targeting and reduce the systemic toxicity associated with the free TLR7/8 agonist; this derivative was further assessed in combination with paclitaxel for synergistic anti-tumor efficacy.

Polymersome-based delivery represents another avenue of active investigation. One study compared the immunostimulatory potency of resiquimod-loaded polymersomes against a next-generation TLR7/8 agonist (3M-060) encapsulated within the same polymersome scaffold. Using human peripheral blood mononuclear cells (PBMCs) as a readout system, the study found that the alternative agonist elicited stronger induction of proinflammatory cytokines than resiquimod-loaded polymersomes, while retaining the native activity of the free drug — illustrating resiquimod as a benchmark compound against which emerging TLR agonists are evaluated in cancer immunotherapy contexts.

Resiquimod has also been investigated in the context of localized postoperative immunotherapy. A study incorporating resiquimod into a laser-triggered immunomodulatory hydrogel system demonstrated that spatial and temporal control over R848 release — combined with photothermal ablation — could simultaneously destroy residual tumor tissue, initiate T-cell-mediated immune responses, and reverse immunosuppressive signaling in the tumor microenvironment. The integration of resiquimod within such programmable biomaterial platforms underscores the importance of controlled delivery for maximizing its therapeutic window.

Beyond tumor-targeting formulations, a clinical translational study addressed the sex-specific immunobiology of TLR agonism in early-stage melanoma. Comparing the in vitro effects of the TLR9 agonist CpG7909 with those of resiquimod (TLR7/8) on sentinel lymph node single cells derived from female patients, this research aimed to identify the more effective dendritic cell-activating strategy for women. The study reflects a growing recognition that immune responses to TLR agonists differ by biological sex and that such differences may inform personalized immunotherapy selection — an increasingly relevant consideration when arming the sentinel lymph node in melanoma management.

Key Publications

• Dec Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma. (Oncoimmunology, 2026, PMID 42093471): "In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients."
• May ROS-responsive mPEG-PCL nanoparticles for co-delivery of paclitaxel prodrug and R848 in synergistic chemo-immunotherapy. (Biomaterials science, 2026, PMID 41944671): "Herein, we propose a reactive oxygen species (ROS)-responsive nanoplatform based on mPEG-PCL for the co-delivery of a paclitaxel (PTX) prodrug and the TLR7/8 agonist R848."
• May Phenylboronic acid modification and small-molecule assembly to enhance the safety of resiquimod and its synergistic anti-tumor efficacy with paclitaxel. (Colloids and surfaces. B, Biointerfaces, 2026, PMID 41638952): "To overcome the systemic toxicity and poor tumor targeting of the TLR7/8 agonist R848, this study developed a derivative by attaching a phenylboronic acid (PBA) group to R848."
• Apr Temporally Programmed and Laser-Triggered Immunomodulatory Hydrogel Enables Synergistic Wound Healing and Prevention of Postoperative Tumor Recurrence. (ACS applied materials & interfaces, 2026, PMID 41995291): "Subsequent laser irradiation triggers the release of MPDA and R848 from PR-Lip, enabling localized ablation of residual tumors, initiating potent T-cell-mediated immune responses, and reversing the immunosuppressive tumor microenvironment."
• Apr Polymersome-based targeted delivery of TLR7/8 agonists enhances cancer immunotherapy. (Journal of materials chemistry. B, 2026, PMID 41948966): "ACM-3M-060 elicited stronger induction of pro-inflammatory cytokines than resiquimod (R848) loaded polymersomes (ACM-R848) in human peripheral blood mononuclear cells (PBMCs), while preserving the native activity of the free drug."